Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company announced positive top-line results from a Phase 2b study of VK2809.
What To Know: Viking Therapeutics said the Phase 2b trial studying its novel liver-selective thyroid hormone receptor beta agonist in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) met its primary endpoint.
Patients receiving VK2809 experienced statistically significant reductions in liver fat content compared to the placebo. The median relative change from baseline in liver fat ranged from 38% to 55%.
“These results demonstrate VK2809’s impressive potency at reducing liver fat, which we believe represent the largest reductions reported for an oral agent at this stage of development,” stated Brian Lian, CEO of Viking Therapeutics.
The company said it plans to report results of the 52-week biopsy data from this study in the first half of next year.
See Also: What’s Going On With Rumble Stock Today?
VKTX Price Action: Viking shares were up 7.5% at $23.64 at the time of writing, according to Benzinga Pro.
Photo: Chokniti Khongchum from Pixabay.
